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 The use of radioisotopes in the UK can be traced from the fi rst tracer study carried 
out by George von Hevesy. Von Hevesy was born in Hungary studied in Germany 
and came to work with Ernest Rutherford in Manchester in 1911. His task was to 
separate Radium D from lead. He suspected that his landlady was reusing food left 
on his dinner plate. He put some  212 Pb into the left overs and some days later used a 
radiation detector to detect it confi rming that his landlady was in fact recycling his 
food (Fig.  2.1 ).
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 Fig. 2.1  Georges von Hevesy 
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 The early use of radionuclides in the UK was hindered by the McMahon Act in 
the US prohibiting the export of radioisotopes made in reactors until 1947. However 
as one of the peaceful uses of atomic energy UK government money was being 
poured into the Atomic Energy Research Establishment at Harwell to produce 
radioisotopes. Already in 1947 J S Mitchell listed most of the radioisotopes that 
would be used as tracers. The fi rst isotope conference sponsored by Harwell was 
held in Oxford in 1951 Fig.  2.2 [ 1 ]. By 1954 colloidal gold bismuth 206 and phos-
phorus were being produced for therapy and iodine 131 iron 59 chromium 51 for 
human diagnostic procedures. With the support of the Medical Research Council 
medical radioisotope units managed by physicists were being formed. At the 
Hammersmith Hospital the fi rst therapeutic dose of P-32 was used in November 
1947 to treat a young girl with a glioma [ 1 ,  2 ]. By 1954 Professor Sir David Smithers 
at the Royal Cancer Hospital London listed treatments on 96 patients using  32 P,  131 I, 
 24 Na,  82 Br, and  198 Au [ 3 ]. The non-therapeutic use of radioisotopes concentrated 
primarily on human physiology. In 1957 John West studied lung perfusion with 
oxygen-15 produced by the fi rst recently installed cyclotron at the MRC unit at the 
Hammersmith Hospital. Other in vitro studies included those on whole body water, 
blood volume and red cell turnover, calcium metabolism, cardiac and renal 
function.
 The original reference book was that of Veall and Vetter 1958 entitled 
Radioisotopes in Clinical Research and Diagnosis (later edited by Belcher and 
Vetter). Counting was done using home-made circuitry with Geiger Counters. 
Norman Veall devised a circular array of Geiger counters to count urine in a 




Winchester bottle. These were eventually replaced by scalers and ratemeters 
made by E K Cole in Southend and Isotope Developments Ltd Aldermaston 
which later became part of Nuclear Enterprises Edinburgh. Norman Veall is 
remembered by the Norman Veall medal presented to a clinical scientist annually 
at the BNMS. 
 A key development of in vitro studies in the UK was made by Roger Ekins at 
the Middlesex Hospital London who in 1960 enabled the quantitative determi-
nation of thyroid hormones in blood samples using radioactive isotopes and 
specifi c binding proteins [ 4 ]. Radioactive B 12 was produced by J M Bradley at 
the Hammersmith Hospital with high specifi c activity cobalt-56 with the help of 
Glaxo. Direct evidence of B 12 absorption in the ileum in 1959 by found by 
Booth and Mollin who studied the distribution of radioactivity in the intestine 
after oral administration of radio labelled B 12. using a Geiger counter during a 
laparotomy [ 5 ]. 
 In 1949 Ansell and Rotblat in Liverpool made the fi rst radioisotope image in the 
UK of a patient with a retrosternal goiter [ 6 ]. By 1955 the precursor of imaging used 
hand held Geiger counters to plot iso-contours of iodine 131 activity in the thyroid 
gland. Russell Herbert also in Liverpool used a small calcium half inch diameter 
tungstate crystal on an early photo multiplier tube to improve the sensitivity. Early 
single and multibore lead collimators improved the resolution. 
 An early scintillation detector designed for brain studies with Iodine 131 fl uores-
cein was made in March 1951 by Belcher and Evans at the Royal Cancer Hospital 
(now the Royal Marsden Hospital) in London. The photomultiplier tube had to be 
cooled by liquid nitrogen to reduce the background noise. To avoid the possibility 
of frostbite, the patient’s skin and the crystal were separated by a long Perspex light 
guide! 
 Also in 1951 rectilinear scanning was being developed to make iodine 131 thy-
roid imaging easier. The fi rst device in the UK was made at the Royal Cancer 
Hospital London in 1951 to image initially radionuclide sources and then the thy-
roid gland. The Mayneord scanner displayed images on a Cathode Ray Tube, used 
Geiger counters, collimator, background subtraction and a clever raster scanning 
mechanism (Fig.  2.3 ).
 Fig. 2.3  A copy of the paper by Mayneord et al. of the fi rst UK radioisotope scanner presented at 
the 1st Harwell sponsored Oxford conference in 1951 
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 The scanner was preceded in 1950 by that shown by Ziedes des Plantes at the 
London International Radiological Congress [ 7 ]. Benedict Cassen in the US also 
published his paper on a thyroid scanner in Nucleonics 1951. 
 Professor Val Mayneord inventor of the fi rst UK radioisotope scanner and his 
wife Audrey met with Professor Ian Donald inventor of the ultrasound scanning in 
the Nuclear Medicine and Ultrasound Department at the Royal Marsden Hospital in 
Sutton Fig.  2.4 .
 The fi rst home made whole body scanner with a colour print out was built in 
1957 at the Hammersmith Hospital by Mallard and Peachey [ 8 ]. Also home-made 
was the fi rst UK digital whole body SPECT scanner in Aberdeen. The fi rst com-
mercial Tri-D scanner was installed in the Royal Marsden Hospital Sutton in 1963. 
It lacked adequate collimation and soon after a 3″ Picker rectilinear scanner was 
purchased. In the days before ultrasound I-131 labeled albumin was used to 
 Fig. 2.4  Professor Val Mayneord inventor of the radioisotope scanner and his wife Audrey with 
Professor Ian Donald inventor of ultrasound scanning. In the background is Professor Kit Hill, 





demonstrate the position of the placenta! Fig.  2.5 . Those were the days in which 
anything was possible. The burdensome legislation governing the use of radioactiv-
ity was yet to come.
 In the mid 1960s Glass and Westerman installed the UK’s fi rst Anger Gamma 
Camera at the Hammersmith. 
 A local fi rm Ekco Electronics Ltd in Southend constructed an Anger type gamma 
camera in 1964 using 9 photomultipler tubes and a 5 in. cryatal. It was not a great 
commercial success. 
 In 1977 another local fi rm J&P constructed the fi rst UK tomoscanner with the 
assistance of David Keeling and Andrew Todd-Pokropek. It was placed in the 
Middlesex Hospital London for evaluation. Tl 201 scans using it were published in 
1979 from the UK and France. 
 In the early days of renography Marcus Hall a radiotherapist at Canterbury 
Hospital developed a technique to eliminate blood background activity [ 9 ]. A com-
puterized version of this technique was later developed by Britton and Brown in 
1970. 
 1967 was a good year for innovation. The fi rst paper using F-18 produced by the 
MRC cyclotron unit for rectilinear scans of bone showed a massive improvement in 
sensitivity from strontium-89 was published in 1967. With a half life of 109.8 min 
 Fig. 2.5  A photoscan of 
abdomen showing the 
placenta taken with a 3″ 
Picker Magnascanner 
using I-131 labeled 
albumin 
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it was fortunate that the traffi c fl ow and the number of traffi c lights between 
Hammermith and Royal Marsden in Sutton was quite low [ 10 ]. In the same year 
Norman Veall published with Steve Garnett the still used technique for the measure-
ment of Glomerular Filtration Rate [ 11 ]. Initially devised to improve tumour detec-
tion in brain scanning a ratio subtract device was constructed in the physics 
workshop in the Institute of Cancer Research in Sutton Surrey in 1967 [ 12 ]. Later 
the device was used to eliminate the liver uptake of seleno-methionine in pancreas 
scanning [ 13 ]. The same technique was performed on an early digital computer by 
Intertechnique Fig.  2.6 . It is interesting to refl ect on how exciting such awful images 
were. In fact this was a good example since many pancreas images consisted of 
about 15 dots.
 In 1969 Roy Parker with his colleagues from the Atomic Weapons Research 
Establishment developed the fi rst semiconductor camera [ 14 ]. Using a cooled ger-
manium detector clear images of a rat’s tiny thyroid were shown at an IAEA Medical 
Radioisotope Scintigraphy meeting in Vienna long before the invention of the cur-
rent solid state cameras. Kromek in the UK is currently advancing CZT technology 
to provide similar high resolution solid state SPECT camera imaging without the 
need for cooling. 
 Fazio and Jones at the Hammersmith reported in 1975 on the use of the generator 
produced 13 s half life  81m Kr for gamma camera imaging of regional lung ventila-
tion. The 190 Kev gamma ray emission complimented  99m Tc 140 Kev emission there 
by enabling simultaneous ventilation; perfusion imaging. The  81 Rb/ 81m Kr generator 
was developed by Clark and Watson who responded to the demand for this 4.7 h 
half-life generator across the UK. As a result at one point  81m Kr/  99m Tc based ventila-
tion: perfusion imaging was the second most frequent imaging procedure in the UK 
after  99m Tc bone scanning. 
 As the krypton generator was delivered to the individual hospitals only once or 
twice per week it was important for patients to have their suspected pulmonary 
 Fig. 2.6  Se-75 methionine 
pancreatic scan imaged on 




embolus on those days only! 1977 saw the fi rst use of I-123 hippuran for gamma 
camera renography by O’Reilly and colleagues in Manchester [ 15 ]. 
 Following the demonstration of dopamine receptors in the brain by Henry 
Wagner in 1983 Imaging Dopamine Receptors in the Human Brain by Positron 
Tomography using 3-N-[ 11 C]methylspiperone. Steve Garnett et al. who had left 
Guys Hospital for McMaster Canada had imaged F18 fl uoro-dopa with their home 
built brain PET scanner to show the distribution of dopamine in the basal ganglia 
published in Nature in 1983 and John Crawley in the UK demonstrated dopamine 
receptors in human brain with   77  Br-p-bromospiperone the benefi t of Br-77 being its 
57 h half life [ 16 ]. In 1985 Peter Ell and his colleagues at the Middlesex Hospital 
published the world fi rst cerebral blood fl ow image using the Amersham produced 
Tc99m labeled HM-PAO [ 17 ]. 
 In the early 1980s, studies with the UK’s fi rst commercial PET scanner at the 
MRC’s Cyclotron Unit at Hammersmith demonstrated the Warburg effect of anaero-
bic glycolysis of human tumors by showing that gliomas preferred to metabolize glu-
cose ( 18 FDG) to oxygen ( 15 O). It was also reported for the fi rst time by Nolop that lung 
tumors have a high uptake of  18 FDG. This set the scene for the introduction of clinical 
PET world-wide where  18 FDG Lung cancer PET imaging was the fi rst procedure to be 
reimbursed in the USA. Also the enhanced uptake of  18 FDG in breast cancer was 
reported by Beaney at that time. It should also be noted that the fi rst use of FDG was 
in the UK by Bessel et al. who explored its use as an anti-cancer agent [ 18 ] 
 The introduction of Sr-89 by Amersham International (Metastron) led to a study 
of a treatment for painful bone metastases from prostate cancer by the Southampton 
Group in 1991. A randomized trial of 32 patients showed the benefi t of the treatment 
against stable strontium [ 19 ]. In 2002 a grant from the National Institutes of Health 
enabled the Royal Marsden/Institute of Cancer Research group to test the feasibility 
and toxicity of high activities of Rhenium-186 hydroxyethylidene diphosphonate, 
with peripheral blood stem cell rescue in patients with progressive hormone refrac-
tory prostate cancer metastatic to bone [ 20 ]. It was hoped that the high activities 
would ablate the metastases as well as relieving bone pain. The long term results of 
that study are being evaluated. 
 More recently in 2013 the Royal Marsden published a multicentre Phase 3 study 
on the use of Re-223 for the palliation of bone pain on the effect on overall survival 
from metastases from castration resistant prostate cancer. The result showed a sig-
nifi cant improvement on overall survival [ 21 ]. 
 The fi rst administration of radioiodine for thyroid cancer in the UK was given by 
Sir Eric Pochin in 1949. While the results from the use of radioiodine thyroid cancer 
have been excellent as early as 1964 Pochin was already recording untoward side 
effects from its use. There remains controversy on the balance between giving high 
activities to ensure total eradication of any residual disease and giving low activities 
to minimize the risks and shorten isolation in the hospital. 
 A fi rst UK wide randomised HiLo study compared the effectiveness of 30 and 
90 mCi of I-131 for post operative ablation of residual thyroid tissue. In the paper 
published in the New England Journal of Medicine in 2012 the results of the HiLo 
study opened the possibility of a complete change in practice reducing the post 
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operative ablative administered activity [ 22 ]. Following the success of that trial a 
new UK nation-wide study comparing the administration of Iodine 131 with none 
in low risk patients is being carried out. 
 The UK can be proud of its long record of the development of radionuclide stud-
ies. Its input has ranged from the introduction of new radionuclides and techniques, 
the development of new equipment, and the use of radionuclides in a wide variety 
of diseases. It is fortunate that the innovation and research continues with the devel-
opment at Kings of Ga-68 compounds which should widen the use of high resolu-
tion PET imaging both in the number of applications and its spread to centres distant 
from the cyclotrons. 
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the work’s Creative Commons license and the respective action is not permitted by statutory regu-
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 Ralph McCready  I graduated from Queens University Belfast with a BSc in Physiology and my 
medical degree. As a houseman I worked in the Royal Victoria Hospital for Dr Frank Pantridge 
who invented the defi brillator. I was fascinated by his catheter laboratory and decided to study 
physiology in radiology. I moved to Guy’s Hospital London to study for an MSc in Radiation 
Physics and Biology together with a Diploma in Medical Radiological Diagnosis (DMRD). 
My next position was an S.H.O in the Radiology Department of the Hammersmith Hospital where 
I used to assist Professor Steiner at the beginning of interventional radiology. During a locum in 
the newly opened Royal Marsden Hospital in Sutton I was offered a research position in the 
Institute of Cancer Research in the Isotope Unit by Dr E.O. Field. Early publications included 
mediastinal lymph node scanning in 1967 and F-18 imaging of bone metastases also in 1967 . 
 Eventually I became a Consultant in Nuclear Medicine in charge of the Nuclear Medicine and 
Ultrasound Department for over 40 years. With Nuclear Medicine and the Medical Physics depart-
ments at either end of the same corridor I was fortunate to be able to take part in many projects 
involving innovations in nuclear medicine, ultrasound equipment magnetic resonance spectros-
copy and radiopharmacy. It was privilege to work with Nigel Trott, Bob Ott and Maggie Flower, 
Martin Leach, Kit Hill and Glenn Flux amongst others. In 1973 I was awarded the Barclay Prize 
by the British Institute of Radiology for my contributions to the British Journal of Radiology. I was 
awarded a DSc in the Faculty of Science of Queens University in 1987. In 1974 I was elected to a 
Fellowship of the Royal College of Physicians London and in 1975 was conferred a Fellow of the 
Royal College of Radiologists London. I was conferred an Honorary Fellowship of the Faculty of 
Radiologists, Royal College of Surgeons, Ireland in 1992 and in 2004 was made an Honorary 
Member of the Japanese Radiological Society. In 1978 I was a vice president of the European 
Nuclear Medicine Society the chairman of the task group on Education and Training of the EANM 
1988–1991 which preceded the European School of Nuclear Medicine. 
 Now retired I still enjoy publishing and presenting at National and International meetings. I am 
a Professor Emeritus at the Institute of Cancer Research London and an Honorary Consultant at the 
Royal Sussex County Hospital in Brighton, U.K. 
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